Role of iron in the natural history and clinical course of hepatitis C disease

Hepato-Gastroenterology

Volumn 45, Issue 20, 1998, Pages 349-355

  Shedlofsky, Steven I ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DEFEROXAMINE; FERRITIN; IRON; RECOMBINANT ALPHA INTERFERON;

DRUG EFFICACY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IRON OVERLOAD; IRON STORAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; OXIDATIVE STRESS; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; IRON; IRON OVERLOAD; LIVER; MALE; OXIDATIVE STRESS; PHLEBOTOMY;

EID: 0031980673     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Morgan EH: Iron metabolism and transport. In Hepatology: A Textbook of Liver Disease, 3rd Edition (Eds., Zakim D, Boyer TD) Saunders, Phil. 1996; pp526-554.
2. Lash A, Saleem A: Iron metabolism and its regulation. Annals Clin Lab Sci 1995; 25:20-30.
3. Weinberg ED: Iron Withholding; a defense against infection and neoplasia. Physiol Rev 1984; 64:65-102.
4. Bonkovsky HL, Banner BF, Lambrecht RW et al: Iron in liver diseases other than hemochromatosis. Sem Liver Dis 1996; 16:65-82.
5. Heubers HA, Finch CA: Transferrin: physiologic behavior and clinical implications. Blood 1984; 64:763-767.
6. Robinson WS: Biology of human hepatitis viruses. In Hepatology: A Textbook of Liver Disease, 3rd Edition. (Eds., Zakim D, Boyer TD) Saunders, Phil. 1996; pp1146-1206.
7. Koff RS: Viral Hepatitis. In Diseases of the Liver, 7th Edition, (Eds., Schiff L, Schiff ER) Lippincott, Phil. 1993; pp492-577.
8. Bacon BR, Tavill AS: Hemochromatosis and the iron overload syndromes. In Hepatology: A Textbook of Liver Disease, 3rd Edition. (Eds., Zakim D, Boyer TD) Saunders, Phil. 1996; pp1439-1489.
9. Verdon R, Pol S, Landais P et al: Absence of Association Between HLA antigens and chronicity of viral hepatitis in hemodialyzed patients. J Hepatol 1994; 21:388-93.
10. Vitte RL, Fortier C, Richardet JP et al: HLA antigens in patients with chronic hepatitis C. Tissue Antigens 1995; 45:356-361.
11. Piperno A, D'Alba R, Fargion S et al: Liver iron concentrations in chronic viral hepatitis. Eur J Gastroenterol Hepatol 1995; 7:1203-8.
12. Feder JN, Gnirke A, Thomas W et al: A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nature Genetics 1996; 13:399-408.
13. Di Bisceglie AM, Axiotis CA, Hoofnagle JH et al: Measurement of iron status in patients with chronic hepatitis. Gastro 1992; 102:2108-13.
14. Haque S, Chandra B, Gerber MA et al: Iron overload in patients with chronic hepatitis C. Human Path 1996; 27:1277-81.
15. Andant CC, Lamoril J, Edery J et al: Hepatic iron concentration and serum iron parameters in patients with chronic hepatitis. Hepatol 1996; 24:478A [Abstr].
16. Hayashi H, Takikawa T, Nishimura N et al: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastro 1994; 89:986-8.
17. Han SH, Fong TL, Valinluck B et al: Randomized controlled trial of the effect of iron depletion on aminotransferase levels, HCV RNA and response to interferon therapy in patients with chronic hepatitis C virus. Hepatol 1995; 22:180A [Abstr].
18. D'Alba R, Sampietro M, Fargion S et al: Iron stores and virus genotypes in chronic hepatitis C: relation with a-interferon response. Hepatol 1995; 22:180A [Abstr].
19. Beinker NK, Voigt MD, Arendse M et al: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996; 25:633-638.
20. Vergani A, Bovo G, Parma S et al: Relationship between iron and histological grading and staging in chronic hepatitis. Hepatol 1996; 24:594A [Abstr].
21. Jamal CM, Arora S, Quinn PG: Serum ferritin is a marker for cirrhosis secondary to hepatitis C. Gastro 1996; 110:A1221 [Abstr].
22. Guido M, Rugge M, Leandro P et al: Hepatic iron overload in chronic hepatitis C: effect on hepatic stellate cells activation. Hepatol 1996; 24:517A [Abstr].
23. Bissell D M, Maher J J: Hepatic Fibrosis and Cirrhosis in Hepatology. A Textbook of Liver Disease. 3rd Edition (Eds.,: Zakim D, Boyer T D) Saunders, Phil 1996; pp506-525.
24. Ramm GA, Li SCY, Li L, Britton RS, Oneill R, Kobayashi Y, Bacon BR: Chronic iron overload causes activation of rat lipocytes in vivo. Am J Physiol 1995; 31:G451-8.
25. Causse X, Godinot H, Chevallier M et al: Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastro 1991; 101:497-502.
26. Tine F, Magrin S, Craxi A, Pagliaro L: Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J. Hepatol 1991; 13:192-9.
27. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994; 20:410-15.
28. Olynyk JK, Reddy KR, Di Bisceglie AM et al: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastro 1995; 108:1104-9.
29. Barton AL, Banner BF, Cable EE, Bonkovsky HL: Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Path 1995; 103:419-424.
30. Arber N, Moshkowitz M, Konikoff F et al: Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. Dig Dis Sci 1995; 40:2431-33.
31. Izumi N, Enomoto N, Uchihara M et al: Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C: relationship to genotypes of hepatitis C virus. Dig Dis Sci 1996; 41:989-994.
32. Celikel CA, Ozdogan O, Eren F et al: Hepatic iron and fibrosis score as predictors of response to interferon in chronic hepatitis C. Gastro 1996; 110:A1165 [Abstr].
33. Montagnese F, Fiore P, Gandin C et al: Prevalence of Iron Overload in Patients With Chronic Viral Hepatitis. Gastro 1996; 110:A1268 [Abstr].
34. Bacon BR, Rebholz AE, Fried M, Di Besceglie AM: Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-a. Hepatol 1993; 18:150A [Abstr].
35. Piperno A, Sampietro M, D'Alba R et al: Iron stores, response to a-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16:248-254.
36. Rossaro L, Farinati F, Boccia S et al: Randomized cross-over trial of phlebotomy and interferon for chronic hepatitis C in patients with high ferritin levels. Gastro 1996; 110:A1307 [Abstr].
37. Kugelmas M, Lieberman BY, Carey WD: Deironization in chronic hepatitis C patients previously non-responsive to interferon improves transaminases but not viral activity. Gastro 1995; 108:A1104 [Abstr].
38. Kugelmas M, Carey WD: Serum cytokine response to phlebotomy in chronic hepatitis C. Gastro 1996; 110:A1242 [Abstr].
39. Van Thiel DH, Friedlander L, Molloy PJ et al: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastro 1996; 43:1557-61.
40. Cohen A, Martin M, Schwartz E: Depletion of excessive liver iron stores with desferrioxamine. Br J Hematol 1984; 58:369-74.
41. Sievert W, Allwell L, Bowden D et al: Hepatic iron content does not predict a sustained response to interferon in patients with thalassemia major and hepatitis C. Gastro 1996; 110:A1326 [Abstr].
42. Bayraktar Y, Koseoglu T, Kayhan B et al: The use of desferrioxamine infusions to enhance the response rate to interferon a (IFN) treatment of chronic viral hepatitis. Gastro 1995; 108:A1031 [Abstr]. 16(6)1322-6.
43. Bayraktar Y, Koseoglu T, Kayhan B et al: The use of desferrioxamine infusions to enhance the response rate to interferon a (IFN) treatment of chronic viral hepatitis. Gastro 1995; 108:A1031 [Abstr]. 16(6)1322-6.
44. Freedman MH, Boyden M, Taylor M, Skarf B: Neurotoxicity associated with deferoxamine therapy. Toxicol 1988; 49:283-90.
45. Fargion S, Piperno A, Capellini M et al: Hepatis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatol 1992; 16:1322-6.
46. DeCastro M, Sanchez J, Herrera J et al: Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatol 1993; 17:551-7.
47. Herrero C, Vicente A, Bruguera M et al: Is Hepatitis C infection a trigger of porphyria cutanea tarda? Lancet 1993; 341:788-9.
48. Sweeney GD: Porphyria Cutanea Tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin Biochem 1986; 19:3-15.
49. Sinclair PR, Bement WJ, Bonkovsky HL, Sinclair JF: Inhibition of uroporphyrinogen decarboxylase by halogenated biphenyls in chick hepatocyte cultures. Biochem J 1984; 222:737-748.
50. Smith AG, Francis J, Green J et al: Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls. Biochem Pharmacol 1990; 40:2059-68.
51. Jacobs JM, Sinclair PR, Bement WJ, Lambrecht RW, Sinclair JF, Goldstein JA: Oxidation of uroporphyrinogen by methylcholanthrene-induced cytochrome P-450. Biochem J 1989; 258:247-253.
52. Pimstone NR: Porphyria Cutanea Tarda. Seminars Liver Disease 1982; 2:(2)132-142.
53. Beloqui O, Prieto J, Suarez M et al: N-acetyl cysteine enhances the response to interferon-a in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13:279-82.
54. Meister, A: Glutathione. in The Liver: Biology and Pathobiology, 2nd Edition, (Eds., Arias IM, Jakoby WB, Popper H, Schachter D, Shafritz DA) Raven Press, NY 1988: pp401-417.
55. Farinati F, Cardin R, Demaria N et al: Iron storage, lipid peroxidation, and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22:449-456.
56. Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH: Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21:1109-12.